Your browser doesn't support javascript.
loading
Prospective direct comparison of biologic treatments for severe eosinophilic asthma: Findings from the PRISM study.
Pham, Duong Duc; Lee, Ji-Hyang; Kwon, Hyouk-Soo; Song, Woo-Jung; Cho, You Sook; Kim, Hyunkyoung; Kwon, Jae-Woo; Park, So-Young; Kim, Sujeong; Hur, Gyu Young; Kim, Byung Keun; Nam, Young-Hee; Yang, Min-Suk; Kim, Mi-Yeong; Kim, Sae-Hoon; Lee, Byung-Jae; Lee, Taehoon; Park, So Young; Kim, Min-Hye; Cho, Young-Joo; Park, ChanSun; Jung, Jae-Woo; Park, Han Ki; Kim, Joo-Hee; Moon, Ji-Yong; Adcock, Ian; Bhavsar, Pankaj; Chung, Kian Fan; Kim, Tae-Bum.
Affiliation
  • Pham DD; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Lee JH; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kwon HS; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Song WJ; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Cho YS; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kim H; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kwon JW; Department of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, Korea.
  • Park SY; Division of Pulmonary, Allergy and Critical Care Medicine, Chung-Ang University Gwangmyeong Hospital, Korea.
  • Kim S; School of Medicine, Department of Internal Medicine, Kyungpook National University, Daegu, Korea.
  • Hur GY; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  • Kim BK; Department of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, Korea.
  • Nam YH; Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
  • Yang MS; Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
  • Kim MY; Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • Kim SH; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Lee BJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Lee T; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Park SY; Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.
  • Kim MH; Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
  • Cho YJ; Department of Allergy and Clinical Immunology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
  • Park C; Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.
  • Jung JW; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
  • Park HK; Department of Allergy and Clinical Immunology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Kim JH; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
  • Moon JY; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
  • Adcock I; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Bhavsar P; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Chung KF; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Kim TB; Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: tbkim@amc.seoul.kr.
Ann Allergy Asthma Immunol ; 132(4): 457-462.e2, 2024 Apr.
Article in En | MEDLINE | ID: mdl-37977324
BACKGROUND: Although various monoclonal antibodies have been used as add-on therapy for severe eosinophilic asthma (SEA), to the best of our knowledge, no direct head-to-head comparative study has evaluated their efficacy. OBJECTIVE: To compare the efficacy of reslizumab, mepolizumab, and dupilumab in patients with SEA. METHODS: This was a multicenter, prospective observational study in patients with SEA who had received 1 of these biologic agents for at least 6 months. Cox proportional hazard models were used to compare the risk of the first exacerbation event, adjusting for sputum or blood eosinophils and common asthma-related covariates. The annual exacerbation rate was analyzed using a negative binomial model, and a mixed-effect model was used to analyze changes in forced expiratory volume in 1 second and asthma control test score over time. RESULTS: A total of 141 patients with SEA were included in the analysis; 71 (50%) received dupilumab; 40 (28%) received reslizumab, and 30 (21%) received mepolizumab. During the 12-month follow-up, 27.5%, 43.3%, and 38.0% of patients in the reslizumab, mepolizumab, and dupilumab groups, respectively, experienced at least 1 exacerbation. However, after adjusting for confounding factors, the dupilumab and mepolizumab groups showed similar outcomes in time-to-first exacerbation, exacerbation rate, forced expiratory volume in 1 second, and asthma control test score to those of the reslizumab group. CONCLUSION: In patients with SEA, treatment with reslizumab, mepolizumab, and dupilumab resulted in comparable clinical outcomes within a 12-month period. TRIAL REGISTRATION: The cohort protocol was sanctioned by the Institutional Review Board of each study center (clinicaltrial.gov identifier NCT05164939).
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Eosinophilia / Asthma / Biological Products / Anti-Asthmatic Agents Limits: Humans Language: En Journal: Ann Allergy Asthma Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Eosinophilia / Asthma / Biological Products / Anti-Asthmatic Agents Limits: Humans Language: En Journal: Ann Allergy Asthma Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Country of publication: